Гормональная и химиотерапия у больных гормоночувствительным раком предстательной железы
https://doi.org/10.17650/1726-9776-2016-12-1-63-68
Аннотация
Рак предстательной железы (РПЖ) является наиболее распространенным онкологическим заболеванием у мужчин в развитых странах мира и вторым в ряду причин смертности в этой популяции. Представленный обзор посвящен терапии распространенных форм РПЖ. Подходы к лечению данной нозологии быстро меняются и продолжают развиваться. В последние годы появилось много новой информации о природе РПЖ. Новые терапевтические агенты и подходы продемонстрировали свои преимущества в увеличении общей выживаемости и качества жизни у пациентов с распространенными формами РПЖ.
Об авторе
Р. А. Гафанов
ФГБУ «Российский научный центр рентгенорадиологии» Минздрава России
Россия
Россия
кандидат медицинских наук, старший научный сотрудник научно-исследовательского отдела комплексной диагностики и лечения заболеваний органов мочеполовой системы у взрослых и детей,
117997, Москва, ул. Профсоюзная, 86
Список литературы
1. Schröder F.H., Hugosson J., Roobol M.J. et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012;366: 981–90.
2. Huggins C, Hodges C.V. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002;168:9–12.
3. Denis L.J., Keuppens F., Smith P.H. et al. Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center. Eur Urol 1998;33:144–51.
4. Singer E.A., Golijanin D.J., Miyamoto H. et al. Androgen deprivation therapy for prostate cancer. Expert Opin Pharmacother 2008;9:211–28.
5. Feldman B.J., Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34–45.
6. Debes J.D., Tindall D.J. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004;351:1488–90.
7. Scher H.I., Buchanan G., Gerald W. et al. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer 2004;11:459–76.
8. Gelmann E.P. Molecular biology of the androgen receptor. J Clin Oncol 2002;20:3001–15.
9. Labrie F. Adrenal androgens and intracrinology. Semin Reprod Med 2004;22:299–309.
10. Trapman J., Cleutjens K.B. Androgenregulated gene expression in prostate cancer. Semin Cancer Biol 1997;8:29–36.
11. Chen Y., Sawyers C.L., Scher H.I. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 2008;8:440–8.
12. Edwards J., Krishna N.S., Grigor K.M. et al. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 2003;89:552–6.
13. Mostaghel E.A., Page S.T., Lin D.W. et al. Intraprostatic androgens and androgenregulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 2007;67:5033–41.
14. Tannock I.F., de Wit R., Berry W.R. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502–12.
15. Petrylak D.P., Tangen C.M., Hussain M.H. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513–20.
16. Pound C.R., Partin A.W., Epstein J.I. et al. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 1997;24:395–406.
17. D’Amico A.V., Whittington R., Malkowicz S.B. et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969–74.
18. D’Amico A.V., Cote K., Loffredo M. et al. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 2002;20:4567–73.
19. Bastian P.J., Boorjian S.A., Bossi A. et al. High-risk prostate cancer: from definition to contemporary management. Eur Urol 2012;61:1096–106.
20. Kattan M.W., Eastham J.A., Stapleton A.M. et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766–71.
21. Eastham J.A., Kelly W.K., Grossfeld G.D. et al. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology 2003;62:55–62.
22. Fizazi K., Lesaunier F., Delva R. et al. A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial. Eur J Cancer 2012;48:209–17.
23. Sandler H.M, Chen Hu, Rosenthal S.A. et al. A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521). J Clin Oncol 2015;33(Suppl), abstr LBA5002.
24. Schweizer M.T., Huang P., Kattan M.W. et al. Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials. Cancer 2013;119:3610–8.
25. Attard G., Sydes M.R., Mason M.D. et al. Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial. Eur Urol 2014;66:799–802.
26. James N.D., Sydes M.R., Mason M.D. et al. Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet Oncol 2012;13:549–58.
27. James N.D., Sydes M.R., Mason M.D. et al. Docetaxel and/or zoledronic acid for hormonenaïve prostate cancer: First overall survival results from STAMPEDE. J Clin Oncol 2015;(suppl) abstr 5001.
28. James N.D., Spears M.R., Clarke N.W. et al. Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). Eur Urol 2015;67:1028–38.
29. Sweeney C., Chen Y.H., Carducci M.A. et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. J Clin Oncol 2014;32:abstr LBA2.
30. Gravis G., Fizazi K., Joly F. et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013;14:149–58.
31. Fontana D., Bertetto O., Fasolis G. et al. Randomized comparison of goserelin acetate versus mitomycin C plus goserelin acetate in previously untreated prostate cancer patients with bone metastases. Tumori 1998;84:39–44.
32. Murphy G.P., Beckley S., Brady M.F. et al. Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 1983;51:1264–72.
33. Murphy G.P., Huben R.P., Priore R. Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer. Urology 1986;28:36–40.
34. Osborne C.K., Blumenstein B., Crawford E.D. et al. Combined versus sequential chemoendocrine therapy in advanced prostate cancer: final results of a randomized Southwest Oncology Group study. J Clin Oncol 1990;8:1675–82.
35. Pummer K., Lehnert M., Stettner H. et al. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur Urol 1997;32:81–5.
36. Janknegt R.A., Boon T.A., van de Beek C. et al. Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: a randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. The Dutch Estracyt Study Group. Urology 1997;49:411–20.
37. Millikan R.E., Wen S., Pagliaro L.C. et al. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol 2008;26:5936–42.
38. Wang J., Halford S., Rigg A. et al. Adjuvant mitozantrone chemotherapy in advanced prostate cancer. BJU Int 2000;86:675–80.
39. Gravis G., Boher J.M., Joly F. et al. Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormonenaïve metastatic prostate cancer (PCa): Longterm analysis of the GETUG-AFU 15 phase III trial. J Clin Oncol 2015;abstr 140.
40. Sweeney C.J., Chen Y.H., Carducci M. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015;373(8):737–46.
41. Eisenberger M.A., Blumenstein B.A., Crawford E.D. et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998;339:1036–42.
42. Recine F., Sternberg C.N. Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer. Transl Androl Urol 2015;4(3):355–64. doi: 10.3978/j.issn.2223-4683.2015.04.11.
Рецензия
Для цитирования:
Гафанов Р.А. Гормональная и химиотерапия у больных гормоночувствительным раком предстательной железы. Онкоурология. 2016;12(1):63-68. https://doi.org/10.17650/1726-9776-2016-12-1-63-68
For citation:
Gafanov R.A. Hormonal therapy and chemotherapy in patients with hormone-sensitive prostate cancer. Cancer Urology. 2016;12(1):63-68. https://doi.org/10.17650/1726-9776-2016-12-1-63-68
Просмотров:
1180
Послать статью по эл. почте 
